C. Fletcher, J. A. Bridge, P. Hogendoorn, and F. Mertens, WHO Classification of Tumours of Soft Tissue and Bone, 2013.

N. Penel, J. M. Coindre, and S. Bonvalot, Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France, Eur J Cancer, vol.58, pp.90-96, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01812682

B. Kasper, P. Stroebel, and P. Hohenberger, Desmoid tumors -clinical features and treatment options for advanced disease, Oncologist, vol.16, pp.682-693, 2011.

B. Kasper, C. Baumgarten, and S. Bonvalot, on behalf of the Desmoid Working Group. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients' and professionals' expertise -a Sarcoma Patients EuroNet (SPAEN) and European Organisation For Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) initiative, Eur J Cancer, vol.51, pp.127-136, 2015.

S. Huss, J. Nehles, and E. Binot, b-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis, Histopathology, vol.62, pp.294-304, 2013.

L. Guellec, S. Soubeyran, I. Rochaix, and P. , CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics, Mod Pathol, vol.25, pp.1551-1558, 2012.

E. Andritsch, M. Beishon, and S. Bielack, ECCO essential requirements for quality cancer care: soft tissue sarcoma in adults and bone sarcoma. A critical review, Crit Rev Oncol Hematol, vol.110, pp.94-105, 2017.

J. M. Cates and T. P. Stricker, Surgical resection margins in desmoid-type fibromatosis: a critical reassessment, Am J Surg Pathol, vol.38, pp.1707-1714, 2014.

W. L. Wang, C. Nero, and A. Pappo, CTNNB1 genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm, Pediatr. Dev Pathol, vol.15, pp.361-367, 2012.

C. Colombo, S. Bolshakov, and S. Hajibashi, 0 Difficult to diagnose 0 desmoid tumours: a potential role for CTNNB1 mutational analysis, Histopathology, vol.59, pp.336-340, 2011.

A. M. Crago, J. Chmielecki, and M. Rosenberg, Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis, Genes Chromosomes Cancer, vol.54, pp.606-615, 2015.

A. J. Lazar, D. Tuvin, and S. Hajibashi, Specific mutations in the betacatenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors, Am J Pathol, vol.173, pp.1518-1527, 2008.

J. Dô-mont, S. Salas, and L. Lacroix, High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management, Br J Cancer, vol.102, pp.1032-1036, 2010.

C. Colombo, R. Miceli, and A. J. Lazar, CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study, Cancer, vol.119, pp.3696-3702, 2013.

D. L. Van-broekhoven, C. Verhoef, and D. J. Grünhagen, Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis, Ann Surg Oncol, vol.22, pp.1464-1470, 2015.

B. Kasper, V. Gruenwald, and P. Reichardt, Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoidtype fibromatosis treated with imatinib: translational research results from a phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01), Ann Surg Oncol, vol.23, pp.1924-1927, 2016.

S. Otero, E. C. Moskovic, and D. C. Strauss, Desmoid-type fibromatosis, Clin Radiol, vol.70, pp.1038-1045, 2015.

U. Bashir, E. Moskovic, and D. Strauss, Soft-tissue masses in the abdominal wall, Clin Radiol, vol.69, pp.422-431, 2014.

J. C. Lee, J. M. Thomas, and S. Phillips, Aggressive fibromatosis: MRI features with pathologic correlation, AJR Am J Roentgenol, vol.186, pp.247-254, 2006.

T. E. Hartman, T. H. Berquist, and J. F. Fetsch, MR imaging of extraabdominal desmoids: differentiation from other neoplasms, AJR Am J Roentgenol, vol.158, pp.581-585, 1992.

J. C. Healy, R. H. Reznek, and S. K. Clark, MR appearances of desmoid tumors in familial adenomatous polyposis, AJR Am J Roentgenol, vol.169, pp.465-472, 1997.

G. Castellazzi, D. Vanel, L. Cesne, and A. , Can the MRI signal of aggressive fibromatosis be used to predict its behaviour?, Eur J Radiol, vol.69, pp.222-229, 2009.

E. A. Walker, J. M. Petscavage, and P. L. Brian, Imaging features of superficial and deep fibromatoses in the adult population, Sarcoma, vol.2012, p.215810, 2012.

M. Sundaram, M. H. Mcguire, and F. Schajowicz, Soft-tissue masses: histologic basis for decreased signal (short T2) on T2-weighted MR images, AJR Am J Roentgenol, vol.148, pp.1247-1250, 1987.

M. M. Gounder, R. A. Lefkowitz, and M. L. Keohan, Activity of sorafenib against desmoid tumor / deep fibromatosis, Clin Cancer Res, vol.17, pp.4082-4090, 2011.

M. Maruzzo, J. Martin-liberal, and C. Messiou, Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience, Clin Sarcoma Res, vol.2, p.5, 2015.

P. A. Dinauer, C. J. Brixey, and J. T. Moncur, Pathologic and MR imaging features of benign fibrous soft-tissue tumors in adults, Radiographics, vol.27, pp.173-187, 2007.

J. H. Rhim, J. H. Kim, and K. C. Moon, Desmoid-type fibromatosis in the head and neck: CT and MR imaging characteristics, Neuroradiology, vol.55, pp.351-359, 2013.

E. A. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumors: re-vised RECIST guideline (version 1.1), Eur J Cancer, vol.45, pp.228-247, 2009.

M. D. Murphey, C. M. Ruble, and S. M. Tyszko, From the archives of the AFIP: musculoskeletal fibromatoses-radiologic-pathologic correlation, Radiographics, vol.29, pp.2143-2173, 2009.

B. Kasper, A. Dimitrakopoulou-strauss, and L. R. Pilz, Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib, Biomed Res Int, p.389672, 2013.

J. J. Lewis, P. J. Boland, and D. H. Leung, The enigma of desmoid tumors, Ann Surg, vol.229, pp.866-872, 1999.

S. Bonvalot, H. Eldweny, and V. Haddad, Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients, Eur J Surg Oncol, vol.34, pp.462-468, 2008.

M. Fiore, F. Rimareix, and L. Mariani, Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment, Ann Surg Oncol, vol.16, pp.2587-2593, 2009.

S. Briand, O. Barbier, and D. Biau, Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors, J Bone Joint Surg Am, vol.96, pp.631-638, 2014.

C. Colombo, R. Miceli, L. Péchoux, and C. , Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients, Eur J Cancer, vol.51, pp.186-192, 2015.

S. Bonvalot, N. Ternes, and M. Fiore, Spontaneous regression of primary abdominal wall desmoids: more common than previously thought, Ann Surg Oncol, vol.20, pp.4096-4102, 2013.

S. Roussin, C. Mazouni, and F. Rimareix, Toward a new strategy in desmoid of the breast?, Eur J Surg Oncol, vol.41, pp.571-576, 2015.

S. M. Burtenshaw, A. J. Cannell, and E. D. Mcalister, Toward observation as first-line management in abdominal desmoid tumors, Ann Surg Oncol, vol.23, pp.2212-2219, 2016.

S. Salas, A. Dufresne, and B. Bui, Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation, J Clin Oncol, vol.29, pp.3553-3558, 2011.

A. M. Crago, B. Denton, and S. Salas, A prognostic nomogram for prediction of recurrence in desmoid fibromatosis, Ann Surg, vol.258, pp.347-353, 2013.

D. L. Van-broekhoven, D. J. Grünhagen, and T. Van-dalen, Tailored betacatenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention, BMC Cancer, vol.16, p.686, 2016.

M. Fiore, S. Coppola, and A. J. Cannell, Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk, Ann Surg, vol.259, pp.973-978, 2014.

S. Bonvalot, F. Rimareix, and S. Causeret, Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoidtype fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient, Ann Surg Oncol, vol.16, pp.3350-3357, 2009.

D. L. Van-broekhoven, J. P. Deroose, and S. Bonvalot, Isolated limb perfusion using tumour necrosis factor a and melphalan in patients with advanced aggressive fibromatosis, Br J Surg, vol.101, pp.1674-1680, 2014.

J. L. Kujak, P. T. Liu, G. B. Johnson, and M. R. Callstrom, Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors, Skeletal Radiol, vol.39, pp.175-182, 2010.

J. J. Schmitz, G. D. Schmit, and T. D. Atwell, Percutaneous cryoablation of extraabdominal desmoid tumors: a 10-year experience, AJR Am J Roentgenol, vol.207, pp.190-195, 2016.

, Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.25, issue.3, pp.102-112, 2014.

R. B. Keus, R. A. Nout, and J. Y. Blay, Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis-an EORTC STBSG and ROG study (EORTC 62991-22998), Ann Oncol, vol.24, pp.2672-2676, 2013.

J. Kriz, H. T. Eich, and U. Haverkamp, Radiotherapy is effective for desmoid tumors (aggressive fibromatosis)-long-term results of a German multicenter study, Oncol Res Treat, vol.37, pp.255-260, 2014.

T. F. Delaney and R. Haas, Innovative radiotherapy of sarcoma: proton beam radiation, Eur J Cancer, vol.62, pp.112-123, 2016.

M. L. Janssen, D. L. Van-broekhoven, and J. M. Cates, Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis, Br J Surg, vol.104, pp.347-357, 2017.

T. J. Wood, K. M. Quinn, and F. Farrokhyar, Local control of extraabdominal desmoid tumors: systematic review and meta-analysis, Rare Tumors, vol.5, p.2, 2013.

X. Yao, T. Corbett, and A. A. Gupta, A systematic review of active treatment options in patients with desmoid tumours, Curr Oncol, vol.21, pp.613-629, 2014.

J. J. Nuyttens, P. F. Rust, C. R. Thomas, A. T. Turrisi, and . Iii, Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles, Cancer, vol.88, pp.1517-1523, 2000.

J. Janinis, M. Patriki, and L. Vini, The pharmacological treatment of aggressive fibromatosis: a systematic review, Ann Oncol, vol.14, pp.181-190, 2003.

M. Al-jazrawe, M. Au, and B. Alman, Optimal therapy for desmoid tumors: current options and challenges for the future, Expert Rev Anticancer Ther, vol.15, pp.1443-1458, 2015.

S. Kummar, O. Coyne, G. Do, and K. T. , Clinical Activity of the c-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis), J Clin Oncol, vol.35, issue.14, pp.1561-1569, 2017.

M. Fiore, C. Colombo, and S. Radaelli, Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis, Eur J Cancer, vol.51, pp.2800-2807, 2015.

D. R. Quast, R. Schneider, and E. Burdzik, Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients, Fam Cancer, vol.15, pp.31-40, 2016.

S. X. Skapek, J. R. Anderson, and D. A. Hill, Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a children's oncology group (COG) phase II study, Pediatr Blood Cancer, vol.60, pp.1108-1112, 2013.

I. Mitra, Z. Szucs, and M. Libertini, Aggressive fibromatosis response to tamoxifen: MRI features with symptomatic correlation-the Royal Marsden experience, CTOS Annual Meeting, 2016.

S. X. Skapek, W. S. Ferguson, and L. Granowetter, Vinblastine and methotrexate for desmoid fibromatosis in children: results of a pediatric oncology group phase II trial, J Clin Oncol, vol.25, pp.501-506, 2007.

D. Garbay, L. Cesne, A. Penel, and N. , Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG), Ann Oncol, vol.23, pp.182-186, 2012.

O. Mir, C. Rahal, and F. Rimareix, Efficacy of oral vinorelbine in advanced/progressive desmoid tumours: an updated retrospective study in 50 patients, J Clin Oncol, vol.34, 2016.

E. Palassini, A. M. Frezza, and L. Mariani, Long-term efficacy of methotrexate plus vinblastine / vinorelbine in large series of patients affected by desmoid-type fibromatosis, Cancer J, vol.23, pp.86-91, 2017.

A. Constantinidou, R. L. Jones, and M. Scurr, Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis, Eur J Cancer, vol.45, pp.2930-2934, 2009.

A. Pang, D. Macedo, M. Carbini, and R. G. Maki, Pegylated liposomal doxorubicin (PLD) as an active treatment option for desmoid tumor (DT) patients, J Clin Oncol, vol.34, 2016.

M. C. Heinrich, G. A. Mcarthur, and G. D. Demetri, Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumour), J Clin Oncol, vol.24, pp.1195-1203, 2006.

N. Penel, L. Cesne, A. Bui, and B. N. , Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up, Ann Oncol, vol.22, pp.452-457, 2011.

B. Kasper, V. Grünwald, and P. Reichardt, Phase II study evaluating imatinib to induce progression arrest in RECIST progressive desmoid tumors not amenable to surgical resection with R0 intent or accompanied by unacceptable function loss-a study of the German Interdisciplinary Sarcoma Group (GISG), Ann Oncol, vol.25, p.494, 2014.

B. Kasper, V. Gruenwald, and P. Reichardt, Imatinib induces sustained progression arrest in RECIST progressive desmoid tumors-final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG), Eur J Cancer, vol.76, pp.60-67, 2017.

R. R. Munhoz, R. A. Lefkowitz, and D. Kuk, Efficacy of sorafenib in patients with desmoid-type fibromatosis, J Clin Oncol, vol.34, 2016.

Z. Szucs, C. Messiou, and H. H. Wong, Pazopanib, a promising option in the landscape of treatment for aggressive fibromatosis, Anticancer Drugs, vol.28, pp.421-426, 2017.

N. B. Merchant, J. J. Lewis, and J. M. Woodruff, Extremity and trunk desmoid tumors: a multifactorial analysis of outcome, Cancer, vol.86, pp.2045-2052, 1999.

A. Gronchi, P. G. Casali, and L. Mariani, Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution, J Clin Oncol, vol.21, pp.1390-1397, 2003.

D. Lev, D. Kotilingam, and C. Wei, Optimizing treatment of desmoid tumors, J Clin Oncol, vol.25, pp.1785-1791, 2007.

K. Huang, H. Fu, and Y. Q. Shi, Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution, J Surg Oncol, vol.100, pp.563-569, 2009.

J. T. Mullen, T. F. Delaney, and W. K. Kobayashi, Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series, Ann Surg Oncol, vol.19, pp.4028-4035, 2012.

D. L. Van-broekhoven, C. Verhoef, and S. G. Elias, Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis, Br J Surg, vol.100, pp.1214-1219, 2013.

J. T. Mullen, T. F. Delaney, and A. E. Rosenberg, b-Catenin mutation status and outcomes in sporadic desmoid tumors, Oncologist, vol.18, pp.1043-1049, 2013.